Dr. Fujun Hu 胡福军
Chief Physician
Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Intensity-modulated radiation therapy and comprehensive care for nasopharyngeal, laryngeal, hypopharyngeal, maxillary sinus, and oral cancers. Also treats brain tumors with combined chemoradiotherapy and provides radiation therapy for pediatric tumors.
Dr. Hu graduated from Zhejiang University School of Medicine in 1990 and has worked in the Radiation Oncology Department at Zhejiang Cancer Hospital since then. Specializing in head and neck tumor radiation therapy, Dr. Hu has authored nearly 20 papers and contributed to two books. Research interests include glioma radioresistance and nasopharyngeal carcinoma treatment.
Professional roles
- Member, Oral Oncology Professional Committee, Zhejiang Anti-Cancer Association
- Vice Chair, Pediatric Oncology Professional Committee, Zhejiang Anti-Cancer Association
Name order: in Chinese the family name comes first (Hu Fujun). Papers usually list the name as Fujun Hu or Hu F.
Selected publications
8 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Medicine (Baltimore), 2018 (senior author): Clinical and prognostic analyses of 110 patients with N3 nasopharyngeal carcinoma. PubMed 30544441
- Cancer Manag Res, 2018 (senior author): A comparison of neoadjuvant chemotherapy with gemcitabine versus docetaxel plus cisplatin in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis. PubMed 30538570
- J Cancer, 2018 (senior author): Neoadjuvant Chemotherapy with Fluorouracil plus Nedaplatin or Cisplatin for Locally Advanced Nasopharyngeal Carcinoma: a Retrospective Study. PubMed 30405836
- Mol Med Rep, 2016 (senior author): Downregulation of miR‑429 and inhibition of cell migration and invasion in nasopharyngeal carcinoma. PubMed 26936585
- Onco Targets Ther, 2015 (senior author): miR-195 is a key regulator of Raf1 in thyroid cancer. PubMed 26527888
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion